Presentations include late-breaking results of six-month pooled analysis of data from the RADIANCE™ Global Clinical Trial Program Palo Alto, Calif. – October 20, 2023 – Recor
The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.
Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to sham.
Ms. Barghout brings more than 20 years of experience leading global businesses in the medical device industry.
The Paradise uRDN System is designed to reduce sympathetic nerve activity by denervating nerves which surround the renal arteries with the goal of reducing blood pressure.
The results come from analysis of the pooled data from ReCor’s RADIANCE Global Clinical Trial Program.
